Orphazyme CFO on failed trial: "Highly disappointing and highly surprising"

Monday's announcement that Orphazyme's main candidate, arimoclomol, for treating degenerative muscle disease IBM has not met its effect targets is highly disappointing and surprising, says the firm's CFO. Now, the company considers scaling back its efforts in the area.

Orpazyme CFO and interim CEO Anders Vadsholt. | Photo: Orphazyme / PR

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

WS Audiology plans to list subsidiary

Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list, which handles online sales.

Further reading

Related articles

Latest news

See all jobs